Virology Journal

Table 5 Comparison of mental health related factors between groups at the baseline and end of the study

From: A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients

Variable	Magnesium group		Placebo group
Variable	Value	P¹	Value	P¹	P²	P³
SF-36 MCS score
Baseline	63.50 ± 16.90	0.003	66.19 ± 19.26	0.109	0.38
End of the study	78.59 ± 15.73	0.003	68.22 ± 17.43	0.109	0.03
Changes	15.09 ± 11.90		2.03 ± 10.52		< 0.001	0.03
SF-36 PCS score
Baseline	78.36 ± 17.45	0.001	80.16 ± 20.15	0.39	0.45
End of the study	95.14 ± 19.22	0.001	83.44 ± 18.67	0.39	0.03
Changes	16.78 ± 14.32		3.28 ± 12.35		0.01	0.02
BDI total score
Baseline	21.98 ± 1.5	0.001	20.75 ± 1.44	0.53	0.87
End of the study	16.78 ± 1.83	0.001	19.12 ± 1.65	0.53	0.12
Changes	-5.24 ± 0.76		-1.63 ± 0.68		0.03	0.03
State anxiety
Baseline	42.15 ± 26.33	0.03	17.43 ± 2.25	0.04	0.31
End of the study	36.19 ± 27.19	0.03	15.68 ± 3.72	0.04	0.08
Changes	-5.96 ± 15.53		-2.92 ± 13.63		0.104	0.126

P1, Paired sample t-test; P2, Independent sample t-test; P3, ANCOVA adjusted for weight, energy intake and serum magnesium levels at baseline; SF-36 MCS, SF-36 mental component score; SF-36 PCS, Physical component score; BDI, Beck’s Depression Inventory

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com